Back

BPTF cooperates with MYCN and MYC to link neuroblastoma cell cycle control to epigenetic cellular states

Felipe, I.; Martinez de Villarreal, J.; Patel, K.; Martinez-Torrecuadrada, J. L.; Grossmann, L. D.; Roncador, G.; Cubells, M.; Farrel, A.; Nathan, K.; Sabroso-Lasa, S.; Sancho-Trevino, L.; Torres, K.; Martinez, D.; Munoz-Peralta, J.; Garcia, F.; Pogoriler, J.; Moreno, L.; Maris, J.; Real, F. X.

2024-02-12 genomics
10.1101/2024.02.11.579816 bioRxiv
Show abstract

The nucleosome remodeling factor BPTF is required for the deployment of the MYC-driven transcriptional program. Deletion of one Bptf allele delays tumor progression in mouse models of pancreatic cancer and lymphoma. In neuroblastoma, MYCN cooperates with the transcriptional core regulatory circuitry (CRC). High BPTF levels are associated with high-risk features and decreased survival. BPTF depletion results in a dramatic decrease of cell proliferation. Bulk RNA-seq, single-cell sequencing, and tissue microarrays reveal a positive correlation of BPTF and CRC transcription factor expression. Immunoprecipitation/mass spectrometry shows that BPTF interacts with MYCN and the CRC proteins. Genome-wide distribution analysis of BPTF and CRC in neuroblastoma reveals a dual role for BPTF: 1) it co-localizes with MYCN/MYC at the promoter of genes involved in cell cycle and 2) it co-localizes with the CRC at super-enhancers to regulate cell identity. The critical role of BPTF across neuroblastoma subtypes supports its relevance as a therapeutic target.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.